Dimerix LimitedASX: DXB

Investor Update

· Issued by Dimerix Limited

Filed with ASX · · 15 pages · English

MELBOURE, Australia; 11 April 2017: Dimerix Limited (ASX: DXB), a clinical stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today published a copy of its latest investor presentation. The presentation highlights a number of clinical and corporate milestones including: -Dimerix is on track to release fin

Dimerix Limited on 6ix

Earlier from Dimerix

Later from Dimerix

All Dimerix news releases